NASDAQ: OABI
Omniab Inc Earnings Dates, Reports, Calls

Omniab earnings were -$61.3M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest OABI earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$18.2M, up 39.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, OABI reported annual earnings of -$62.0M, with 22.5% growth.

OABI earnings history

Current Revenue
$26.7M
Current Earnings
-$61.3M
Current Profit Margin
-229.1%

OABI Return on Equity

Current Company
-21.4%
Current Industry
-60.2%
Current Market
31.3%
OABI's Return on Equity (-21.4%)... subscribe to Premium to read more.
High Return on Equity Performance

OABI undefined

Current Company
-18.8%
Current Industry
-2.5%
OABI is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when OABI announces earnings.

OABI undefined

Current Company
-23.12%
Current Industry
5.8%

OABI vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
OABI-$44.76M-$61.27MN/A-$0.59
NGNE-$76.91M-$80.87MN/A-$4.35
CRDF-$48.32M-$48.88MN/A-$0.92
MDWD-$18.84M-$21.22MN/A-$2.04
LCTX-$15.61M-$16.21MN/A-$0.08

Omniab Earnings Reports & History FAQ

What were Omniab's earnings last quarter?

On OABI's earnings call on Invalid Date, Omniab (NASDAQ: OABI) reported Q1 2025 earnings per share (EPS) of -$0.17, up 10.53% year over year. Total OABI earnings for the quarter were -$18.20 million. In the same quarter last year, Omniab's earnings per share (EPS) was -$0.19.

If you're new to stock investing, here's how to buy Omniab stock.

Is Omniab profitable or losing money?

As of the last Omniab earnings report, Omniab is currently losing money. Omniab's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$61.27 million, a 3.48% decrease year over year.

What was OABI's earnings growth in the past year?

As of Omniab's earnings date in Invalid Date, Omniab's earnings has grown year over year. OABI earnings in the past year totalled -$61.27 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.